• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 14th August 2018

The Impact of New Medicines in the NHS: 70 Years of Innovation

This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts. This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.

This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.

For 70 years, the NHS has provided coverage for a range of approved medical and pharmaceutical interventions. Over this period, many new medicines have been developed in the UK and overseas, to which the NHS has provided patients access. But which of these new medicines have had the greatest impact?

Our new Consulting Report describes work funded by the Association of the British Pharmaceutical Industry (ABPI) to try and answer this question. The report demonstrates the contribution and impact of medicines to the health economy in the UK throughout the 70-year history of the NHS. Through qualitative interviews with experts we identified a shortlist of the most important medicines to have been brought to market, and from a review of the literature and evidence base we attempt to quantify the benefits of these key medicines in terms of health and economic outcomes.

Our interviews with experts identified a shortlist of ten important new medicines introduced in the NHS in the last 70 years, which were selected from a longer list of 37 on the basis of the qualitative evidence.

The ten medicines are:

  • Chlorpromazine
  • Polio vaccine
  • Oral contraceptives
  • Second to fourth generation penicillins
  • Beta blockers
  • Beta2 agonists
  • Tamoxifen
  • Immunosuppressants
  • HIV/AIDS antiretrovirals
  • MMR vaccine

We identified a variety of benefits encompassing improvement in clinical outcomes, survival benefits, quality of life improvement, greater health service efficiency, and wider societal impacts.

But the question of which medicines have had the greatest impact is not an easy one to answer. The level of quantification of the benefits is variable, meaning that it is difficult to definitively aggregate their value.

We used the qualitative interviews to identify factors that have played an important role in determining the impact of new medicines. Seven themes arose from the interviews relating to i) the value of innovation, ii) complementarity and spillovers, iii) substitution, iv) policy, v) evidence, vi) understanding, and vii) collaboration. These themes highlight a variety of ways in which policymakers can facilitate positive impact from new medicines. Their role should be considered in the use of medicines in the NHS over the next 70 years and for new medicines currently in the development pipeline.

Download the full report here.

Download the press release from the ABPI here.

 

Citation

Sampson, C., O’Neill, P. & Lorgelly, P. 2018. The Impact of New Medicines in the NHS: 70 Years of Innovation. OHE Consulting Report, London: Office of Health Economics.

Related research

Davies, S.C. 2017. Ten Years of the NIHR: Achievements and Challenges for the Next Decade. OHE Monograph, London: Office of Health Economics. RePEc

Hicks, N. 2017. Delivering an Outcomes-based NHS: Creating the Right Conditions. OHE Seminar Briefing, London: Office of Health Economics. RePEc

O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. 2013. Projecting Expenditure on Medicines in the UK NHS. PharmacoEconomics 31(10), 933-957. DOI | RePEc

  • Health Data and Statistics
  • Economics of Innovation
  • Consulting Reports

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!